Coming Down the Pike: Treating Epilepsy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Coming Down the Pike: Treating Epilepsy


Pharmaceutical Technology
Volume 33, Issue 3, pp. 20
Scientists studying epilepsy have traditionally focused on the comings and goings of ions through molecular channels in nerve cells, and many current antiseizure therapies seek to modulate that dynamic. However, some people don't respond to channel-based therapies, causing scientists to look further for other molecular activities to target therapeutically in epilepsy management. A recent report suggests they may have found one. A paper published in Nature Medicine points to a possible inflammatory interaction between white blood cells and blood-vessel walls that appears to damage the barrier that prevents unwanted substances from flowing into or out of the brain, the so-called blood–brain barrier. The researchers found an increase in "sticky" adhesion molecules on both white blood cells and on the cells lining the blood vessels in the brain of mice in whom epileptic-like seizures had been induced. This interaction, they proposed, might be therapeutically blocked by monoclonal antibodies, thus reducing the severity and incidence of seizures. Source: P.F. Pabene et al., "A Role for Leukocyte–Endothelial Adhesion Mechanisms in Epilepsy," Nature Medicine 14, 1377–1383 (2008).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here